IM Cannabis Q2 Loss Widens to C$4.4M; Going Concern Doubts and Nasdaq Delisting Risk
IMCC sits 35% above its 52-week low of $0.097 on light trading volume (0.1× avg).
Summary
IM Cannabis reported a widening Q2 loss, going concern doubts, and Nasdaq delisting risk, alongside continued dilutive financing.
Key Events · Earnings and Guidance · IMCC
-
Q2 Loss Widens
Net loss of C$4.4 million for Q2 2026, compared to a C$0.2 million loss in Q2 2025. Revenue fell 40% to C$7.6 million.
-
Going Concern Doubts
Negative working capital of C$13.1 million, accumulated deficit of C$276.7 million, and shareholders' deficit of C$5.5 million. Management states substantial doubt about continuing as a going concern.
-
Nasdaq Delisting Risk
Received notice on April 9, 2026 for non-compliance with the $1.00 minimum bid price rule. Compliance deadline is October 6, 2026.
-
Dilutive Financings Continue
Subsequent to quarter end, closed two convertible note offerings on July 1 and August 7, 2026, raising US$225K and US$250K principal with warrants for 1.48M and 2.05M shares at exercise prices of $0.22 and $0.17.
Analysis · IMCC · Life Sciences
A sharp deterioration in quarterly results underscores the precarious state of IM Cannabis. The company posted a net loss of C$4.4 million for Q2 2026, compared with a C$0.2 million loss a year earlier, while revenue fell 40% to C$7.6 million. Its financial position is equally strained: negative working capital of C$13.1 million, an accumulated deficit of C$276.7 million, and a shareholders' deficit of C$5.5 million. Management explicitly states that these conditions raise substantial doubt about the company's ability to continue as a going concern. Adding to the pressure, a Nasdaq notice received on April 9, 2026 flags non-compliance with the $1.00 minimum bid price rule, with a compliance deadline of October 6, 2026. The filing also discloses two subsequent convertible note financings in July and August 2026 with deeply dilutive terms, continuing a pattern of high-cost capital raises. The pending sale of European operations to a CEO-controlled entity remains non-binding, adding further uncertainty.
At the time of this filing, IMCC was trading at $0.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.10 to $2.83. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.